Integrated Biotherapeutics, Inc.
Therapeutic monoclonal antibody (3I14) against influenza virus with broad heterosubtypic neutralizing activity
- Sector
- Biotech
- Headquarters
- Gaithersburg, MD
- Latest Form D
- $1M, May 2023
- Total capital
- $18M
- Federal grants
- $17M
- 28 awards · 2015–2022
- Rank in peer group#13 of 514
- Private capital raised
- $1M
- 1 Form D · last May 2023
- 42 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 21 pending · first 2017
- Rank in peer group#71 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$1M
- Federal grantHealth and Human S · Phase II · Immunotherapy of MRSA Osteomyelitis$1M
- Federal grantHealth and Human S · Phase II · Development of a Universal Immunotherapeutic for Influenza Viruses$351K
- Federal grantHealth and Human S · Phase II · Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis$663K
- Federal grantHealth and Human S · Phase I · Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses$292K
- Federal grantHealth and Human S · Phase II · Immunotherapy of MRSA Osteomyelitis$1M
- Federal grantHealth and Human S · Phase II · Development of a Universal Immunotherapeutic for Influenza Viruses$1.5M
Show 22 earlier federal awards
- Federal grantHealth and Human S · Phase I · Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses$300K
- Federal grantHealth and Human S · Phase II · Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis$985K
- Federal grantHealth and Human S · Phase I · Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein$300K
- Federal grantHealth and Human S · Phase I · Mining natively paired macque antibodies for Marburg virus protective antibodies$300K
- Federal grantHealth and Human S · Phase I · ISTAb- A novel therapy to target staphylococcal toxins at the site of infections$300K
- Federal grantHealth and Human S · Phase I · Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein$300K
- Federal grantHealth and Human S · Phase II · Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis$3M
- Federal grantHealth and Human S · Phase I · ISTAb- A novel therapy to target staphylococcal toxins at the site of infections$600K
- Federal grantHealth and Human S · Phase I · Mining natively paired macque antibodies for Marburg virus protective antibodies$300K
- Federal grantHealth and Human S · Phase II · Development of a Universal Immunotherapeutic for Influenza Viruses$290K
- Federal grantHealth and Human S · Phase I · Remodeled glycoprotein for broad protection against ebolaviruses$299K
- Federal grantHealth and Human S · Phase II · Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$1M
- Federal grantHealth and Human S · Phase I · Remodeled glycoprotein for broad protection against ebolaviruses$302K
- Federal grantHealth and Human S · Phase I · Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis$300K
- Federal grantHealth and Human S · Phase I · Serotype independent therapeutic vaccine for Streptococcus pneumoniae$191K
- Federal grantHealth and Human S · Phase II · Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$1.9M
- Federal grantHealth and Human S · Phase I · Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis$295K
- Federal grantHealth and Human S · Phase I · Serotype independent therapeutic vaccine for Streptococcus pneumoniae$248K
- Federal grantHealth and Human S · Phase I · Broadly Protective Bispecific Antibodies for Treatment of Ebola Virus Disease$230K
- Federal grantHealth and Human S · Phase I · Structure-guided redesign of monoclonal antibodies targeting conserved filovirus epitopes$284K
- Federal grantHealth and Human S · Phase I · In vivo conjugated multivalent toxoid-polysaccharide vaccine for S. aureus$300K
- Federal grantHealth and Human S · Phase I · Infection Site Targeted Antitoxin Antibody (ISTAb) against Clostridium difficile$230K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
99months
from Integrated Biotherapeutics, Inc.’s first federal award to its first private round.
- First federal award · Jan 2015
- Health and Human S · $230K
- First Form D · May 2023
- $1M · 1st Form D
- Awards before first raise
- 28 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#13 · top 3%
- Granted patents#71 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- M JAVAD AMANResearcherExecutive Officer, DirectorLinked by $2.4M in grants as PI
- TARUN JAVAD DENGIDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 26- GrantedTargeting Immunological Functions to the Site of Bacterial Infections Using Cell Wall Targeting Domains of BacteriolysinsUSPTOUS 11,028,153
- GrantedTargeting Immunological Functions To The Site Of Bacterial Infections Using Cell Wall Targeting Domains Of BacteriolysinsUSPTOUS 10,487,140
- GrantedToxoid Peptides Derived From Phenol Soluble Modulin, Delta Toxin, Superantigens, and Fusions ThereofUSPTOUS 10,174,085
Show all 26 patent records
- Targeting Immunological Functions to the Site of Bacterial Infections Using Cell Wall Targeting Domains of BacteriolysinsJun 8, 2021 · US 11,028,153Granted
- Targeting Immunological Functions To The Site Of Bacterial Infections Using Cell Wall Targeting Domains Of BacteriolysinsNov 26, 2019 · US 10,487,140Granted
- Toxoid Peptides Derived From Phenol Soluble Modulin, Delta Toxin, Superantigens, and Fusions ThereofJan 8, 2019 · US 10,174,085Granted
- Pan-ebola And Pan-filovirus Protective Epitopes, Antibodies, And Antibody CocktailsAug 23, 2018 · Application 15556898Pending
- Immunogenic Composition Comprising Panton-Valentine Leukocidin (PVL) Derived PolypeptidesJul 17, 2018 · US 10,023,848Granted
- Immunogenic Composition Comprising Engineered Alpha-hemolysin OligopeptidesMay 24, 2018 · Application 15541108Pending
- Toxoid Peptides Derived From Phenol Soluble Modulin, Delta Toxin, Superantigens, And Fusions ThereofNov 14, 2017 · US 9,815,872Granted
- Monoclonal Antibodies Directed Against Envelope Glycoproteins From Multiple Filovirus SpeciesJun 8, 2017 · Application 15321833Pending
- Immunogenic Composition Comprising Alpha-hemolysin OligopeptidesFeb 11, 2016 · Application 14818817Pending
- Immunogenic Composition Comprising Engineered Alpha-Hemolysin OligopeptidesApplication 62100238Pending
- Monoclonal Antibodies Directed Against Envelope Glycoproteins From Multiple Filovirus SpeciesApplication 62019668Pending
- Monoclonal Antibodies Directed Against Envelope Glycoproteins From Multiple Filovirus SpeciesApplication 62016811Pending
- Toxoid Peptides Derived From Phenol Soluble Modulin, Delta Toxin, Superantigens, And Fusions ThereofApplication PCTUS2014042999Pending
- Ebola Monoclonal AntibodiesApplication 61941775Pending
- Targeting Immunological Functions To The Site Of Bacterial Infections Using Cell Wall Targeting Domains Of BacteriolysinsApplication 61927120Pending
- Immunogenic Composition Comprising Toxoid Peptides Derived From Phenol Soluble Modulin, Delta Hemolysin And Fusions Thereof With Attenuated Alpha Hemolysin Leukocidins And Superantigen ToxoidsApplication 61836959Pending
- Immunogenic Composition Comprising Panton-valentine Leukocidin (pvl) Derived PolypeptidesApplication PCTUS2012067483Pending
- Immunogenic Composition Comprising Alpha-hemolysin OligopeptidesApplication PCTUS2012024031Pending
- Immunogenic Compositions Comprising Staphylococcus Aureus Leukocidin Luka And Lukb DerivedApplication PCTUS2018037376Pending
- Immunogenic Composition Comprising a Fusion Peptide Derived from Superantigen ToxoidsApplication 62537706Pending
- Immunogenic Compositions Comprising Staphylococcus Aureus Leukocidin LukA and LukB Derived PolypeptidesApplication 62518641Pending
- Pan-ebola And Pan-filovirus Protective Epitopes, Antibodies, And Antibody CocktailsApplication PCTUS2016022141Pending
- Immunogenic Composition Comprising Engineered Alpha-hemolysin OligopeptidesApplication PCTUS2016012269Pending
- Monoclonal Antibodies Directed Against Envelope Glycoproteins From Multiple Filovirus SpeciesApplication PCTUS2015037493Pending
- Pan-Ebola and Pan-Filovirus Protective Epitopes, Antibodies, and Antibody CocktailsApplication 62131563Pending
- Targeting Immunological Functions To The Site Of Bacterial Infections Using Cell Wall Targeting Domains Of BacteriolysinsApplication PCTUS2015011455Pending
Related companies, and why
- KINARX, INCShares a founder: FREDERICK HOLTSBERG
- Adaptive Phage Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- RADIKAL THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- CYTONUS THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- BOSTON INTERACTOME LLCSimilar federal contract value in Biotech · null in contracts
- ALEPH THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .